Unique ID issued by UMIN | UMIN000045596 |
---|---|
Receipt number | R000052045 |
Scientific Title | Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in bifidobacteria on skin aging in healthy women |
Date of disclosure of the study information | 2021/09/28 |
Last modified on | 2025/04/04 14:45:59 |
Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in bifidobacteria on skin aging in healthy women
A clinical study of oral probiotics intake and skin aging
Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in bifidobacteria on skin aging in healthy women
A clinical study of oral bifidobacteria intake and skin aging
Japan |
None
Adult |
Others
NO
To investigate the change of skin aging signs and the balance of both skin and gut microflora after 12 weeks of oral intake of bifidobacteria.
Efficacy
VISIA total score after oral intake of bifidobacteria
VISIA sub-scores, the balance of gut microbiota, the balance of skin microbiota, objective evaluation of skin condition, subjective evaluation of skin condition(VAS) after oral intake of bifidobacteria
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
Institution is not considered as adjustment factor.
No need to know
2
Prevention
Food |
Intake of powdered bifidobacteria for 12 weeks
Intake of powdered placebo for 12 weeks
30 | years-old | <= |
Not applicable |
Female
Adult female aged 30 years old or older
Individual who is applicable to any of the conditions below;
1. Taking regular aesthetic procedure or foods (except those who are able to continuously discontinue the act during the study).
2. Having skin problems, requiring medical care to their skin or taking treatment to diseases that could have an influence on their skin.
3. Having major allergic disease or being highly likely to develop those diseases
4. Being under sever diseases or having past history of those diseases.
5. Having medication allergy or severe food allergy.
6. Regularly taking foods, medication or supplement that would have an influence on gut microbiota (4 or more days a week of intake is regarded as regular use).
7. Heavy drinker
8. Smoking more than 20 cigarettes a day
9. Pregnant, willing to pregnant during the study period and continuous breast feeding
10. Currently participating to other clinical trial or past history within a month
11. Judged as not appropriate to this study by a responsible doctor or contributing doctors
130
1st name | Yuriko |
Middle name | |
Last name | Nishikawa |
Juntendo university graduate school of medicine
Department of Microbiota Research
113-0033
3-3-1 Ochanomizu KS Building 405, Hongo, Bunkyo-ku, Tokyo
03(3813)3111
ynishika@juntendo.ac.jp
1st name | Yuriko |
Middle name | |
Last name | Nishikawa |
Juntendo university graduate school of medicine
Department of Microbiota Research
113-0033
3-3-1 Ochanomizu KS Building 405, Hongo, Bunkyo-ku, Tokyo
03(3813)3111
ynishika@juntendo.ac.jp
Juntendo university graduate school of medicine
Department of Microbiota Research
A joint research department between Juntendo University Graduate School of Medicine and Morinaga Milk Industry Co., Ltd.
Other
The Jikei University Kashiwa hospital
Japan Conference of Clinical Research
1-13-23 Minami-ikebukuro, Toshima-ku, Tokyo 171-0022
03(6868)7022
http://www.jccr.jp/
NO
2021 | Year | 09 | Month | 28 | Day |
Unpublished
120
No longer recruiting
2021 | Year | 07 | Month | 16 | Day |
2021 | Year | 07 | Month | 16 | Day |
2021 | Year | 09 | Month | 18 | Day |
2022 | Year | 08 | Month | 31 | Day |
2021 | Year | 09 | Month | 28 | Day |
2025 | Year | 04 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052045